United States Radiopharmaceuticals Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), By Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), and United States Radiopharmaceuticals Market Insights, Industry Trend, Forecasts to 2035

United States Radiopharmaceuticals Market Insights Forecasts to 2035

• The US Radiopharmaceuticals Market Size Was Estimated at USD 6012.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.81% from 2025 to 2035
• The US Radiopharmaceuticals Market Size is Expected to Reach USD 16822.9 Million by 2035

According to a research report published by Spherical Insights & Consulting, the United States Radiopharmaceuticals Market is anticipated to reach USD 16822.9 million by 2035, growing at a CAGR of 9.81% from 2025 to 2035. The expansion of the United States radiopharmaceuticals market is propelled by the growing number of diagnostic centres and the abundance of qualified medical professionals in hospital radiology departments.

Market Overview

A radiopharmaceutical, referred to as a radioactive medication or radiocompound, is a pharmaceutical product that includes one or more radionuclides in a formulation used to either monitor, diagnose, or treat disease by emitting radiation. The radiopharmaceutical market in the US is largely influenced by the increasing rates of chronic diseases, particularly cancer and heart-related issues. Many of the chronic illnesses, which can often be prevented or managed, are linked to five of the top ten leading causes of death. The demand for radiopharmaceuticals has surged due to advancements in molecular imaging, along with the increasing use of single photon emission computed tomography and positron emission tomography. Additionally, the need for early and precise diagnostic tools has grown, driven by an aging population and the rise in age-related health issues, making radiopharmaceuticals a vital component of modern healthcare. A groundbreaking trend in the U.S. radiopharmaceutical market is theranostics, which merges diagnostics with treatment. This innovative approach allows for a tailored and effective treatment plan by using radiopharmaceuticals to both diagnose and treat diseases simultaneously.

The U.S. government promotes radiopharmaceutical innovation through coordinated research, development, and regulatory efforts across the FDA, NIH, DOE, and BARDA. The FDA has released specific guidelines, such as the microdose radiopharmaceutical diagnostic drugs, nonclinical study recommendations, to reduce regulatory burden and expedite clinical translation. These guidelines support imaging-based early human studies and simplify preclinical requirements for PET and SPECT tracer development.

Report Coverage

This research report categorizes the market for the United States radiopharmaceuticals market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States radiopharmaceuticals market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States radiopharmaceuticals market.

Driving Factors

The growth of the United States radiopharmaceuticals market is the rise of personalized medicine. This groundbreaking approach is transforming healthcare by tailoring medical treatments to fit each patient's unique genetic, molecular, and clinical characteristics. With this strategy, we can create highly precise diagnostic and treatment options in the realm of radiopharmaceuticals. By leveraging advanced imaging techniques and developing radiopharmaceuticals that target specific disease markers, healthcare providers can deliver accurate diagnoses and closely track conditions like cancer, heart disease, and neurodegenerative disorders.

Restraining Factors

The United States radiopharmaceuticals market faces obstacles like the relatively short half-lives of many of its products. These brief half-lives, often measured in minutes to hours, limit the time available for producing and administering these compounds.

Market Segmentation

The United States radiopharmaceuticals market share is classified into product type and application.

• The diagnostic nuclear medicine segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The United States radiopharmaceuticals market is segmented by product type into diagnostic nuclear medicine and therapeutic nuclear medicine. Among these, the diagnostic nuclear medicine segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The segment is driven because it includes imaging agents used for early disease detection and monitoring technologies like PET and SPECT. Radiopharmaceuticals such as technetium 99m and fluorine-18 are commonly employed in cardiovascular, neurological, and oncological imaging.

• The oncology segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

Based on the application, the United States radiopharmaceuticals market is segmented into oncology, cardiology, neurology, endocrinology, and others. Among these, the oncology segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is propelled because it is crucial for cancer detection and treatment. For instance, fluorine-18 and lutetium-177 are two radiopharmaceuticals frequently used for targeted radiation and imaging in cancers like thyroid, prostate, and neuroendocrine tumors.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States radiopharmaceuticals market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lantheus Medical Imaging, Inc.
• GE Healthcare
• Positron Corp
• Cardinal Health Inc
• BWXT Medical
• Point Biopharma
• Actinium Pharmaceuticals
• Plus Therapeutics, Inc.
• Cellectar Biosciences
• Others

Recent Development

• In May 2024, Fannin Partners announced the launch of Radiomer Therapeutics with pre-seed funding to further advance its radiopharmaceutical therapy platform based on proprietary Raptamer technology. The platform has been designed for targeting cancers, including breast, lung, and colorectal cancers, and combines high binding affinity with rapid clinical development.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United States radiopharmaceuticals market based on the following segments

United States Radiopharmaceuticals Market, By Product Type

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine

United States Radiopharmaceuticals Market, By Application

• Oncology
• Cardiology
• Neurology
• Endocrinology
• Others